Chugai Pharmaceutical and Rani Therapeutics Collaborate on Oral Delivery Technology for Rare Disease Treatment

"Chugai Pharmaceutical and Rani Therapeutics have entered into a collaboration agreement to develop and commercialize an oral product that combines Rani's oral delivery technology, the RaniPill®, with Chugai's antibody for rare diseases. Latham & Watkins is advising Chugai on the transaction."

Latham & Watkins, LLP advised Chugai Pharmaceutical Co., Ltd. in a recent transaction involving Rani Therapeutics, LLC, a subsidiary of Rani Therapeutics Holdings, Inc. The transaction consists of a Collaboration and License Agreement for the development and commercialization of an oral product that combines Rani’s oral delivery technology, the RaniPill®, with Chugai’s rare disease antibody currently in development. The legal team from Latham & Watkins included partner Chris Hazuka and counsel Darryl Steensma from the San Diego/Bay Area office, along with associates Mizuna Sekine and Patrick Chew. Additionally, partner Ted Dillman provided advice on finance matters from the Los Angeles office, partner Kathleen Wells addressed securities matters from the Bay Area, and partner Kirt Switzer, along with associate Derek Gumm, offered guidance on tax matters, also from the Bay Area.

Chugai Pharmaceutical and Rani Therapeutics Collaborate on Oral Delivery Technology for Rare Disease Treatment

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads